NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

NTRA

Natera Inc

Jun 30 • 04:00PM ET

168.94

Dollar change +0.98
Percentage change 0.58	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN GH TXG EXAS QGEN FLGT TWST MYGN CDNA BNGO

| Held by: VTI VB VXF VBK IWP IBB XBI ARKK IWF IWR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.47	Insider Own	5.25%	Shs Outstand	135.93M	Perf Week	-0.84%
Market Cap	23.07B	Forward P/E	-	EPS next Y	-1.07	Insider Trans	-7.80%	Shs Float	129.38M	Perf Month	6.89%
Enterprise Value	22.27B	PEG	-	EPS next Q	-0.62	Inst Own	94.02%	Short Float	4.82%	Perf Quarter	17.37%
Income	-189.76M	P/S	12.60	EPS this Y	-43.14%	Inst Trans	3.80%	Short Ratio	4.49	Perf Half Y	4.03%
Sales	1.83B	P/B	18.52	EPS next Y	50.93%	ROA	-11.86%	Short Interest	6.24M	Perf YTD	6.72%
Book/sh	9.12	P/C	23.26	EPS next 5Y	-	ROE	-18.66%	52W High	183.00 -7.68%	Perf Year	51.67%
Cash/sh	7.26	P/FCF	270.79	EPS past 3/5Y	33.57% 3.18%	ROIC	-14.13%	52W Low	92.14 83.35%	Perf 3Y	334.85%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	39.47% 41.20%	Gross Margin	61.79%	Volatility	3.67% 3.12%	Perf 5Y	262.30%
Dividend TTM	-	EV/Sales	12.16	EPS Y/Y TTM	53.23%	Oper. Margin	-12.41%	ATR (14)	5.42	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.74	Sales Y/Y TTM	51.50%	Profit Margin	-10.36%	RSI (14)	57.29	Recom	1.41
Dividend Gr. 3/5Y	- -	Current Ratio	3.87	EPS Q/Q	11.22%	SMA20	1.37%	Beta	1.73	Target Price	201.89
Payout	-	Debt/Eq	0.16	Sales Q/Q	36.46%	SMA50	6.37%	Rel Volume	0.76	Prev Close	167.96
Employees	4434	LT Debt/Eq	0.08	Earnings	May 08 AMC	SMA200	11.18%	Avg Volume	1.39M	Price	168.94
IPO	Jul 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.94% 12.46%	Trades		Volume	1,058,240	Change	0.58%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-25	Initiated	RBC Capital Mkts	Outperform	$251
Jan-23-25	Initiated	Barclays	Overweight	$200
Jun-03-24	Resumed	Jefferies	Buy	$142
Apr-08-24	Resumed	Craig Hallum	Buy	$117
Feb-20-24	Downgrade	Raymond James	Strong Buy → Outperform	$68 → $85
Dec-29-23	Reiterated	BTIG Research	Buy	$75 → $85
Dec-14-23	Initiated	Guggenheim	Buy	$70
Dec-13-23	Initiated	Wolfe Research	Outperform	$70
Nov-13-23	Upgrade	Raymond James	Outperform → Strong Buy	$68
Sep-28-23	Initiated	Bernstein	Mkt Perform	$48
Jul-05-23	Resumed	JP Morgan	Overweight	$85
May-05-23	Initiated	UBS	Buy	$76
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$58
Aug-25-22	Initiated	Credit Suisse	Outperform	$70
Apr-25-22	Initiated	Stephens	Overweight	$54
Mar-08-22	Initiated	Goldman	Buy	$90
Jan-06-22	Resumed	Piper Sandler	Overweight	$110
Oct-15-21	Resumed	Cowen	Outperform	$150
Jun-15-21	Initiated	Raymond James	Mkt Perform
May-25-21	Initiated	Wells Fargo	Overweight	$110

Show Previous Ratings

Jun-29-25 11:33PM	Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA) (StockStory)
Jun-24-25 04:25AM	Natera Gains Medicare Coverage for WGS Signatera, Leerink Reaffirms Price Target (Insider Monkey)
Jun-22-25 08:00AM	If You Can Only Buy 1 Cathie Wood Stock in 2025, It Should Be This (Barchart)
Jun-20-25 12:04AM	3 Reasons We Love Natera (NTRA) (StockStory)
Jun-12-25 06:20AM	Should Vanguard Small-Cap Growth ETF (VBK) Be on Your Investing Radar? (Zacks)
06:30AM	Loading…
Jun-10-25 06:30AM	NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase (StockStory)
Jun-04-25 07:00AM	Natera Announces Medicare Coverage for Signatera Genome (Business Wire)
Jun-02-25 04:05PM	SignateraTM Genome Clinical Performance Highlighted at ASCO 2025 (Business Wire)
May-27-25 06:20AM	Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? (Zacks)
May-22-25 05:08PM	Natera to Present over 25 Signatera Studies at 2025 ASCO Annual Meeting (Business Wire)
May-20-25 06:20AM	Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? (Zacks)
May-13-25 10:08AM	Natera, Inc. (NTRA): A Bull Case Theory (Insider Monkey)
May-09-25 07:45AM	Q1 2025 Natera Inc Earnings Call (Thomson Reuters StreetEvents) -6.53%
03:39AM	Natera Inc (NTRA) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Raised Guidance (GuruFocus.com)
May-08-25 08:30PM	Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:55PM	Loading…
05:55PM	Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:54PM	Natera: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports First Quarter 2025 Financial Results (Business Wire)
10:30AM	Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress (Business Wire)
09:18AM	Natera Inc (NTRA) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-07-25 07:55PM	Enhabit (EHAB) Q1 Earnings Top Estimates (Zacks)
12:42PM	Natera Q1 2025 Earnings Preview (Seeking Alpha)
07:00AM	Prospera Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows (Business Wire)
May-06-25 10:24AM	Natera reports outcomes from study of MRD test for soft tissue and bone sarcomas (Medical Device Network)
07:15AM	Pediatrix Medical Group (MD) Q1 Earnings and Revenues Surpass Estimates (Zacks)
May-05-25 07:00AM	Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera (Business Wire)
May-01-25 07:00AM	Natera to Report its First Quarter Results on May 8, 2025 (Business Wire)
Apr-29-25 04:05PM	Prospective DEFINE-HT Study Demonstrates that Prospera Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction (Business Wire)
11:45AM	Baron Health Care Fund Q1 2025 Top Net Purchases And Sales (Seeking Alpha)
09:00AM	2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of (StockStory)
02:22PM	Loading…
Apr-27-25 02:22PM	Baron Health Care Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-24-25 05:21PM	Natera, Inc. (NTRA): One of the Best Aggressive Growth Stocks to Buy Now (Insider Monkey)
07:00AM	Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera Genome MRD Test (Business Wire)
Apr-22-25 04:05PM	Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting (Business Wire)
Apr-17-25 04:15PM	The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It. (Investor's Business Daily)
Apr-08-25 10:03AM	Natera, Inc. (NTRA): Among Stocks with Buy Ratings that Hedge Funds Love (Insider Monkey)
05:13AM	3 Reasons NTRA Has Explosive Upside Potential (StockStory)
Apr-07-25 07:00AM	27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks (Motley Fool)
Apr-02-25 12:20AM	Lord Abbett Growth Leaders Fund Q4 2024 Commentary (Seeking Alpha)
Mar-26-25 11:10AM	Columbia Acorn Fund Q4 2024 Commentary (SeekingAlpha)
Mar-25-25 07:00AM	DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting (Business Wire)
Mar-24-25 12:28PM	Is Natera, Inc. (NTRA) the Best Diagnostics Stock to Invest in Right Now? (InsiderMonkey)
Mar-20-25 08:29AM	Here's What Lifted Natera (NTRA) in Q4 and 2024 (InsiderMonkey)
05:09AM	Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack (StockStory)
Mar-19-25 07:00AM	Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings (Fool)
Mar-18-25 05:39AM	Is Natera (NTRA) the Best Biotech Stock According to Billionaires? (Insider Monkey)
Mar-11-25 03:07PM	Why Is Natera (NTRA) Stock Soaring Today (StockStory) +5.57%
Mar-10-25 08:00AM	Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer (Business Wire) -5.71%
Mar-07-25 09:30AM	Natera (NTRA) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
Mar-04-25 07:00AM	Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD (Business Wire)
Feb-28-25 10:35AM	Q4 2024 Natera Inc Earnings Call (Thomson Reuters StreetEvents)
02:37AM	Natera Inc (NTRA) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements (GuruFocus.com)
Feb-27-25 06:20PM	Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:53PM	Natera (NASDAQ:NTRA) Reports Bullish Q4, Guides for Strong Full-Year Sales (StockStory)
04:05PM	Natera Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-26-25 08:14AM	Natera (NTRA) Q4 Earnings: What To Expect (StockStory)
07:08AM	Natera Inc (NTRA) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-25-25 06:00AM	Natera Announces Medicare Coverage of Signatera for Surveillance in Lung Cancer (Business Wire)
Feb-24-25 02:19PM	Natera, Inc. (NTRA): Among Top Stocks to Buy of Joe DiMennas Portfolio (Insider Monkey)
Feb-19-25 09:55AM	Natera (NTRA) Surged on Blowout Quarterly Results (Insider Monkey)
Feb-18-25 09:00AM	Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025 (Business Wire)
Feb-14-25 03:47PM	Schrodinger Stock Scores IBD Rating Upgrade (Investor's Business Daily)
Feb-10-25 02:51PM	Trade Tracker: Amy Raskin trims Vertex, Natera & Kadant, buys CareDx and Impinj (CNBC TV)
07:00AM	NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma (Business Wire)
Feb-03-25 07:00AM	Natera Announces National Commercial Coverage for its Fetal RhD NIPT (Business Wire)
Jan-28-25 08:02AM	Heres Why Natera (NTRA) Surged in Q4 (Insider Monkey)
Jan-27-25 09:42AM	Natera reports new data from Phase III study of colorectal cancer detection test (Medical Device Network)
Jan-25-25 10:05AM	Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer (Business Wire)
Jan-21-25 06:05PM	Natera to Present New Data at the 2025 ASCO GI Symposium (Business Wire) +5.75%
04:03PM	Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone (Investor's Business Daily)
Jan-17-25 09:00AM	Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year (Business Wire) -6.02%
Jan-16-25 04:05PM	Exact Sciences Stock Drops 11% Over Four Days. 'What Is Going On?' (Investor's Business Daily)
Jan-15-25 07:00AM	Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection (Business Wire)
Jan-12-25 07:20PM	Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024 (Business Wire)
Jan-09-25 08:15AM	Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings (Motley Fool)
Jan-07-25 09:00AM	Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-03-25 02:03PM	Six IBD 50 Stocks Bear Gifts Even As Santa Claus Rally Fizzles (Investor's Business Daily)
Dec-17-24 09:35AM	Natera (NTRA) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
08:00AM	Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomics (Business Wire)
06:53AM	What Makes Natera (NTRA) a Top Stock Pick for Billionaire Stanley Druckenmiller? (Insider Monkey)
Dec-13-24 08:21AM	Natera enrolls 1st patients in SAGITTARIUS clinical trial in colon cancer (TipRanks)
Dec-12-24 08:00AM	Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer (Business Wire)
Dec-09-24 08:00AM	Natera and MyOme Announce Launch of iPRS for Breast Cancer Risk Assessment (Business Wire)
Dec-03-24 08:06AM	Strong Volume Growth Lifted Natera (NTRA) in Q3 (Insider Monkey)
Dec-02-24 02:40PM	Why Is Natera, Inc. (NTRA) Among the Best High Growth Healthcare Stocks to Invest In Now? (Insider Monkey)
08:00AM	Clinical Validation Study on Nateras Fetal RhD NIPT Published in Obstetrics and Gynecology (Business Wire)
05:00AM	Guardant awarded nearly $293M in false ad trial against Natera (MedTech Dive)
Nov-27-24 09:00AM	Natera Announces Medicare Coverage for Prospera in Single Lung Transplant Recipients (Business Wire)
Nov-25-24 07:57PM	Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium (Business Wire)
05:09PM	Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal (PR Newswire)
03:51PM	Natera Issues Statement on Guardant Health Litigation (Business Wire)
09:00AM	Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 RandD Leader of the Year (Business Wire)
Nov-21-24 05:31PM	Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM (Business Wire)
Nov-14-24 09:09PM	Stanley Druckenmiller's Strategic Emphasis on Natera Inc in Q3 2024 (GuruFocus.com) -6.13%
Nov-13-24 10:25AM	Natera Stock Explodes 20% After Record-Breaking Q3--Is This Biotech Giant Just Getting Started? (GuruFocus.com) +19.13%
02:17AM	Natera Inc (NTRA) Q3 2024 Earnings Call Highlights: Record Revenue and Raised Guidance Amid ... (GuruFocus.com)
12:04AM	Decoding Natera Inc (NTRA): A Strategic SWOT Insight (GuruFocus.com)
Nov-12-24 06:30PM	Natera (NTRA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:55PM	Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:48PM	Natera: Q3 Earnings Snapshot (Associated Press Finance)

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	May 16 '25	Sale	152.84	19,000	2,903,900	55,000	Jun 20 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	May 28 '25	Sale	161.00	10,000	1,610,000	35,000	Jun 20 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	May 20 '25	Sale	153.90	10,000	1,539,000	45,000	Jun 20 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	May 15 '25	Sale	150.20	10,000	1,502,000	74,000	Jun 20 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Jun 13 '25	Sale	165.85	5,000	829,250	30,000	Jun 20 09:35 PM
Sheena Jonathan	CO-FOUNDER	Jun 18 '25	Sale	167.29	3,070	513,571	248,774	Jun 20 09:05 PM
Sheena Jonathan	CO-FOUNDER	Jun 16 '25	Sale	164.55	3,000	493,649	37,282	Jun 20 09:05 PM
DANIEL RABINOWITZ	Officer	Jun 18 '25	Proposed Sale	167.55	19,908	3,335,585		Jun 18 04:27 PM
Sheena Jonathan	Director	Jun 18 '25	Proposed Sale	167.30	9,210	1,540,833		Jun 18 10:50 AM
Sheena Jonathan	Director	Jun 16 '25	Proposed Sale	164.56	9,000	1,481,005		Jun 16 12:59 PM
Marcus Gail Boxer	Director	Jun 10 '25	Sale	164.44	4,000	657,761	5,704	Jun 11 09:05 PM
Marcus Gail Boxer	Director	Jun 10 '25	Proposed Sale	164.44	4,000	657,761		Jun 10 02:22 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jun 02 '25	Sale	157.07	3,000	471,212	133,205	Jun 04 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jun 02 '25	Sale	157.10	6,111	960,062	179,071	Jun 04 09:05 PM
SOLOMON MOSHKEVICH	Officer	Jun 02 '25	Proposed Sale	157.07	3,000	471,212		Jun 02 04:28 PM
STEVEN L CHAPMAN	Officer	Jun 02 '25	Proposed Sale	157.10	6,111	960,063		Jun 02 04:27 PM
Sheena Jonathan	CO-FOUNDER	May 09 '25	Sale	160.22	3,070	491,867	251,844	May 13 09:35 PM
Sheena Jonathan	CO-FOUNDER	May 12 '25	Sale	158.26	3,000	474,766	38,782	May 13 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	May 01 '25	Sale	150.10	6,980	1,047,702	185,182	May 02 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	May 01 '25	Sale	150.12	3,000	450,353	136,205	May 02 09:35 PM
Marcus Gail Boxer	Director	May 01 '25	Option Exercise	24.42	4,000	97,680	13,704	May 02 09:35 PM
Marcus Gail Boxer	Director	May 01 '25	Sale	151.61	4,000	606,433	9,704	May 02 09:35 PM
STEVEN L CHAPMAN	Officer	May 01 '25	Proposed Sale	150.10	6,980	1,047,702		May 01 04:06 PM
SOLOMON MOSHKEVICH	Officer	May 01 '25	Proposed Sale	150.12	3,000	450,353		May 01 04:02 PM
Marcus Gail Boxer	Director	May 01 '25	Proposed Sale	151.61	4,000	606,433		May 01 03:41 PM
Sheena Jonathan	CO-FOUNDER	Apr 28 '25	Sale	152.18	439	66,808	254,914	Apr 30 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Apr 28 '25	Sale	152.18	1,718	261,449	2,362,570	Apr 30 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Apr 28 '25	Sale	152.18	1,993	303,300	223,674	Apr 30 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Apr 28 '25	Sale	152.18	2,206	335,714	139,280	Apr 30 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Apr 28 '25	Sale	152.18	1,709	260,080	155,237	Apr 30 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Apr 28 '25	Sale	152.18	6,203	943,987	192,162	Apr 30 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 29 '25	Sale	154.18	3,045	469,484	70,494	Apr 30 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 28 '25	Sale	152.18	2,018	307,104	73,539	Apr 30 09:35 PM
MICHAEL BURKES BROPHY	Officer	Apr 29 '25	Proposed Sale	152.99	3,045	465,855		Apr 29 04:21 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 22 '25	Sale	145.00	911	132,091	75,557	Apr 24 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 24 '25	Sale	152.45	755	115,102	75,557	Apr 24 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 23 '25	Sale	150.74	495	74,616	76,312	Apr 24 09:35 PM
MICHAEL BURKES BROPHY	Officer	Apr 24 '25	Proposed Sale	148.56	755	112,163		Apr 24 04:20 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 21 '25	Sale	145.55	610	88,784	76,468	Apr 22 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Apr 21 '25	Sale	145.55	1,664	242,190	198,365	Apr 22 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Apr 21 '25	Sale	145.55	343	49,922	156,946	Apr 22 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Apr 21 '25	Sale	145.56	296	43,085	141,486	Apr 22 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Apr 21 '25	Sale	145.55	470	68,408	225,667	Apr 22 09:35 PM
Sheena Jonathan	CO-FOUNDER	Apr 21 '25	Sale	145.55	86	12,517	255,353	Apr 22 09:35 PM
MICHAEL BURKES BROPHY	Officer	Apr 22 '25	Proposed Sale	142.23	911	129,572		Apr 22 04:05 PM
Sheena Jonathan	CO-FOUNDER	Apr 03 '25	Sale	139.19	3,000	417,575	40,282	Apr 04 09:35 PM
Sheena Jonathan	CO-FOUNDER	Apr 04 '25	Sale	133.14	3,070	408,751	255,249	Apr 04 09:35 PM
Marcus Gail Boxer	Director	Apr 01 '25	Option Exercise	19.74	4,000	78,967	13,704	Apr 03 08:35 PM
Marcus Gail Boxer	Director	Apr 01 '25	Sale	140.78	4,000	563,100	9,704	Apr 03 08:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Apr 01 '25	Sale	140.48	3,000	421,428	141,782	Apr 03 08:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Mar 31 '25	Sale	138.41	2,562	354,603	75,557	Apr 01 09:45 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Apr 01 '25	Sale	140.48	15,898	2,233,330	196,643	Apr 01 09:45 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 31 '25	Sale	138.41	9,563	1,323,617	212,541	Apr 01 09:45 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Mar 31 '25	Sale	138.41	1,404	194,327	225,281	Apr 01 09:35 PM
STEVEN L CHAPMAN	Officer	Apr 01 '25	Proposed Sale	140.48	15,898	2,233,330		Apr 01 04:19 PM
SOLOMON MOSHKEVICH	Officer	Apr 01 '25	Proposed Sale	140.48	3,000	421,428		Apr 01 04:10 PM
Marcus Gail Boxer	Director	Apr 01 '25	Proposed Sale	140.78	4,000	563,100		Apr 01 03:47 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 17 '25	Sale	146.03	6,702	978,678	203,354	Mar 19 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Mar 17 '25	Sale	146.04	792	115,661	71,869	Mar 19 09:45 PM
Sheena Jonathan	CO-FOUNDER	Mar 18 '25	Sale	145.65	3,000	436,952	41,782	Mar 19 09:35 PM
Sheena Jonathan	CO-FOUNDER	Mar 18 '25	Sale	145.57	2,700	393,027	258,319	Mar 19 09:35 PM
Sheena Jonathan	CO-FOUNDER	Mar 17 '25	Sale	146.03	181	26,431	261,019	Mar 19 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 17 '25	Sale	146.04	1,127	164,584	2,364,288	Mar 19 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Mar 17 '25	Sale	146.04	928	135,521	224,185	Mar 19 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Mar 17 '25	Sale	146.04	1,026	149,836	144,782	Mar 19 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Mar 17 '25	Sale	146.04	795	116,099	157,289	Mar 19 09:35 PM
Sheena Jonathan	Director	Mar 18 '25	Proposed Sale	145.90	17,840	2,602,856		Mar 18 05:18 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 14 '25	Sale	147.70	50,000	7,385,249	2,365,415	Mar 14 09:35 PM
Marcus Gail Boxer	Director	Mar 12 '25	Option Exercise	7.86	4,000	31,440	13,704	Mar 14 09:35 PM
Marcus Gail Boxer	Director	Mar 12 '25	Sale	147.69	4,000	590,773	9,704	Mar 14 09:35 PM
MATTHEW RABINOWITZ	Director	Mar 14 '25	Proposed Sale	147.71	50,000	7,385,250		Mar 14 04:10 PM
Marcus Gail Boxer	Officer	Mar 12 '25	Proposed Sale	147.69	4,000	590,773		Mar 12 04:02 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Mar 05 '25	Sale	143.29	6,000	859,734	143,768	Mar 07 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 05 '25	Sale	143.40	87,272	12,515,006	203,354	Mar 07 09:35 PM
SOLOMON MOSHKEVICH	Officer	Mar 05 '25	Proposed Sale	143.29	6,000	859,734		Mar 05 04:32 PM
STEVEN L CHAPMAN	Officer	Mar 05 '25	Proposed Sale	143.40	87,272	12,515,001		Mar 05 04:17 PM
Sheena Jonathan	CO-FOUNDER	Feb 26 '25	Sale	160.47	3,000	481,419	43,282	Feb 28 09:05 PM
Sheena Jonathan	CO-FOUNDER	Feb 26 '25	Sale	160.54	2,700	433,455	260,789	Feb 28 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Feb 06 '25	Sale	177.77	1,632	290,121	149,768	Feb 07 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Feb 06 '25	Sale	177.77	663	117,862	156,044	Feb 07 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Feb 03 '25	Sale	176.88	43,502	7,694,642	70,629	Feb 04 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 31 '25	Sale	173.05	400	69,220	114,131	Feb 04 09:45 PM
MICHAEL BURKES BROPHY	Officer	Feb 03 '25	Proposed Sale	176.92	43,902	7,767,142		Feb 03 04:22 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 29 '25	Sale	165.87	4,335	719,044	103,697	Jan 31 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 31 '25	Sale	176.60	1,886	333,068	101,811	Jan 31 09:45 PM
Sheena Jonathan	CO-FOUNDER	Jan 29 '25	Sale	165.87	1,054	174,827	260,103	Jan 31 09:35 PM
Sheena Jonathan	CO-FOUNDER	Jan 31 '25	Sale	176.60	163	28,786	259,940	Jan 31 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Jan 29 '25	Sale	165.87	6,003	995,716	2,383,177	Jan 31 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 29 '25	Sale	165.87	4,773	791,694	213,020	Jan 31 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 29 '25	Sale	165.87	5,201	862,688	135,483	Jan 31 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 29 '25	Sale	165.87	4,030	668,454	143,200	Jan 31 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 29 '25	Sale	165.87	13,685	2,269,928	253,944	Jan 31 09:35 PM
MICHAEL BURKES BROPHY	Officer	Jan 31 '25	Proposed Sale	176.27	1,886	332,445		Jan 31 04:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 27 '25	Sale	161.87	1,442	233,417	108,032	Jan 29 09:45 PM
MICHAEL BURKES BROPHY	Officer	Jan 27 '25	Proposed Sale	167.61	1,442	241,694		Jan 27 04:24 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 24 '25	Sale	171.98	946	162,689	109,474	Jan 24 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 23 '25	Sale	171.09	495	84,690	110,420	Jan 24 09:45 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 22 '25	Sale	164.97	24,861	4,101,226	140,684	Jan 24 09:45 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 22 '25	Sale	164.97	21,228	3,501,905	147,230	Jan 24 09:45 PM
MICHAEL BURKES BROPHY	Officer	Jan 24 '25	Proposed Sale	171.82	946	162,542		Jan 24 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTRA

Natera Inc

Upgrade your FINVIZ experience